Literature DB >> 8053746

Outpatient treatment of community-acquired pneumonia in adults.

P V Pomilla1, R B Brown.   

Abstract

Most adults with community-acquired pneumonia are treated as outpatients. Despite this, the majority of studies regarding community-acquired pneumonia have been in hospitalized patients only and may not be applicable to an ambulatory population. This review critically examines the literature regarding the diagnosis, cause, appropriate patient selection, and treatment of nonhospitalized adults with community-acquired pneumonia, including human immunodeficiency virus-infected individuals. English-language articles on oral antibiotic trials for community-acquired pneumonia, obtained from a MEDLINE search from 1966 to the present, are reviewed. Etiologic diagnosis is helpful in determining appropriate outpatient treatment for community-acquired pneumonia, and usually requires only sputum Gram's stain analysis. Viral, mycoplasmal, and chlamydial agents are among the most common pathogens encountered in individuals treated as outpatients, although much variability exists. Many oral antibiotic trials for community-acquired pneumonia have been published, but shortcomings in study design limit their clinical applicability. A treatment algorithm is offered, using the best available data.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8053746

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  2 in total

1.  Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods.

Authors:  E L Fasola; S Bajaksouzian; P C Appelbaum; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

2.  Usefulness of Gram stain for diagnosis of lower respiratory tract infection or urinary tract infection and as an aid in guiding treatment.

Authors:  E J Kuijper; J van der Meer; M D de Jong; P Speelman; J Dankert
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-25       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.